177 related articles for article (PubMed ID: 1900225)
21. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
Hoffmeister HM; Kastner C; Szabo S; Beyer ME; Helber U; Kazmaier S; Baumbach A; Wendel HP; Heller W
Am J Cardiol; 2000 Aug; 86(3):263-8. PubMed ID: 10922430
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
[TBL] [Abstract][Full Text] [Related]
23. Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.
Pedersen OD; Gram J; Jespersen J
Heart; 1997 Feb; 77(2):122-7. PubMed ID: 9068393
[TBL] [Abstract][Full Text] [Related]
24. [Thrombolytic therapy in acute myocardial infarct].
Bode C; Baumann H; von Hodenberg E; Kübler W
Med Klin (Munich); 1992 Feb; 87(2):64-9. PubMed ID: 1542285
[No Abstract] [Full Text] [Related]
25. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
26. Thrombin generation during infusion of tissue-type plasminogen activator.
Genser N; Mair J; Maier J; Dienstl F; Puschendorf B; Lechleitner P
Lancet; 1993 Apr; 341(8851):1038. PubMed ID: 8096940
[No Abstract] [Full Text] [Related]
27. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
28. Thrombin/antithrombin-III complex level as early predictor of reocclusion after successful thrombolysis.
Gulba DC; Barthels M; Reil GH; Lichtlen PR
Lancet; 1988 Jul; 2(8602):97. PubMed ID: 2898711
[No Abstract] [Full Text] [Related]
29. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA.
Garcia-Avello A; Garcia-Frade LJ; Gandarias C; Ocaña J; Cancelas JA; Lasso M
Thromb Res; 1994 Jan; 73(2):109-15. PubMed ID: 8171409
[TBL] [Abstract][Full Text] [Related]
30. Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator.
Andreotti F; Kluft C; Hackett DR; Davies GJ; Maseri A
Lancet; 1993 Oct; 342(8876):937-8. PubMed ID: 8105201
[No Abstract] [Full Text] [Related]
31. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
32. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
Czyrski J
Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
[TBL] [Abstract][Full Text] [Related]
33. Elevation of thrombin-antithrombin complexes during thrombolytic therapy in patients with myocardial infarction.
Tripodi A; Bottasso B; Mannucci PM
Ric Clin Lab; 1990; 20(3):197-202. PubMed ID: 2122514
[TBL] [Abstract][Full Text] [Related]
34. A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the COmbining Monteplase with Angioplasty (COMA) trial.
Inoue T; Yaguchi I; Takayanagi K; Hayashi T; Morooka S; Eguchi Y
Am Heart J; 2002 Oct; 144(4):E5. PubMed ID: 12360174
[TBL] [Abstract][Full Text] [Related]
35. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.
Mak KH; Lee LH; Wong A; Chan C; Koh TH; Lau KW; Lim YL
Am J Cardiol; 2002 Apr; 89(8):930-6. PubMed ID: 11950430
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.
Popma JJ; Califf RM; Ellis SG; George BS; Kereiakes DJ; Samaha JK; Worley SJ; Anderson JL; Stump D; Woodlief L
J Am Coll Cardiol; 1992 Nov; 20(6):1305-12. PubMed ID: 1430679
[TBL] [Abstract][Full Text] [Related]
37. Coronary thrombolysis with clot-selective plasminogen activators.
Collen D; Bounameaux H
Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
[TBL] [Abstract][Full Text] [Related]
38. Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction.
Zahger D; Karagounis LA; Cercek B; Anderson JL; Sorensen S; Moreno F; Shah PK
Am J Cardiol; 1995 Oct; 76(11):749-52. PubMed ID: 7572648
[TBL] [Abstract][Full Text] [Related]
39. Frequency of achieving optimal reperfusion with thrombolysis in acute myocardial infarction (analysis of four German multicenter studies).
Vogt A; von Essen R; Tebbe U; Feuerer W; Appel KF; Niederer W; Neuhaus KL
Am J Cardiol; 1994 Jul; 74(1):1-4. PubMed ID: 8017295
[TBL] [Abstract][Full Text] [Related]
40. Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
Kambara H; Kawai C; Kajiwara N; Niitani H; Sasayama S; Kanmatsuse K; Kodama K; Sato H; Nobuyoshi M; Nakashima M
Circulation; 1988 Oct; 78(4):899-905. PubMed ID: 3139325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
